Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate Academic Article uri icon

Overview

MeSH Major

  • Androgen Antagonists
  • Androstenols
  • Antineoplastic Agents
  • Prostatic Neoplasms

abstract

  • Abiraterone acetate has significant antitumor activity in post-docetaxel patients with CRPC. Randomized, phase III trials of abiraterone acetate are underway to define the future role of this agent.

publication date

  • March 20, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2849770

Digital Object Identifier (DOI)

  • 10.1200/JCO.2009.24.6819

PubMed ID

  • 20159823

Additional Document Info

start page

  • 1489

end page

  • 95

volume

  • 28

number

  • 9